Gestational diabetes mellitus: Non-insulin management
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Gestational diabetes mellitus (GDM) complicates a substantial number of pregnancies. There is consensus that in patients of GDM, excellent blood glucose control, with diet and, when necessary, oral hypoglycemics and insulin results in improved perinatal outcomes, and appreciably reduces the probability of serious neonatal morbidity compared with routine prenatal care. Goals of metabolic management of a pregnancy complicated with GDM have to balance the needs of a healthy pregnancy with the requirements to control glucose level. Medical nutrition therapy is the cornerstone of therapy for women with GDM. Surveillance with daily self-monitoring of blood glucose has been found to help guide management in a much better way than blood glucose checking in labs and clinics, which tends to be less frequent. Historically, insulin has been the therapeutic agent of choice for controlling hyperglycemia in pregnant women. However, difficulty in medication administration with multiple daily injections, potential for hypoglycemia, and increase in appetite and weight make this therapeutic option cumbersome for many pregnant patients. Use of oral hypogycemic agents (OHAs) in pregnancy has opened new vistas for GDM management. At present, there is a growing acceptance of glyburide (glibenclamide) use as the primary therapy for GDM. Glyburide and metformin have been found to be safe, effective and economical for the treatment of gestational diabetes. Insulin, however, still has an important role to play in GDM. GDM is a window of opportunity, which needs to be seized, for prevention of diabetes in future life. Goal of our educational programs should be not only to improve pregnancy outcomes but also to promote healthy lifestyle changes for the mother that will last long after delivery. Team effort on part of obstetricians and endocrinologists is required to make "the diabetes capital of the world" into "the diabetes care capital of the world".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 1×
“Maternal–fetal Medicine Units Network very recently conducted a randomized clinical trial for the treatment of mild gestational diabetes,[6] the results of which provided further compelling evidence that among women who have GDM and normal fasting glucose levels, treatment, as necessary, reduces rates of adverse pregn…”
BackgroundMetzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 1×
“An Australian study (Metformin in Gestational diabetes – MiG study) conducted by Rowan and colleagues included 751 women (371 received metformin, and 378 received insulin) who were randomized between 20 and 33 weeks of pregnancy.[73] The metformin failure rate was 7.”
Low–Glycemic Index Diets in the Management of Diabetes
Brand-Miller, J., Hayne, S., Petocz, P., & Colagiuri, S. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2261 · Cited by 951
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 4×
“[57,58] In contrast, neonatal hyperglycemia was reported by some to be higher among those women who received glyburide (33%) compared with those receiving insulin (4%),[58] whereas others did not find such differences.[53] Dhulkotia et al.”
BackgroundResultInfluentialAmerican Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s88 · Cited by 916
Correlations between Antepartum Maternal Metabolism and Intelligence of Offspring
Rizzo, T., Metzger, B. E., Burns, W. J., & Burns, K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251303 · Cited by 707
de Veciana, M., Major, C. A., Morgan, M. A., Asrat, T., Toohey, J. S., Lien, J. M., & Evans, A. T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331901 · Cited by 666 · cited 1×
“Elevated glucose values, and in particular postprandial glucose elevations, are associated with adverse outcomes in GDM.[40] Carbohydrate is the main nutrient that affects postprandial glucose levels.”
BackgroundMetzger, B. E. (1991) · Diabetes · doi:10.2337/diab.40.2.s197 · Cited by 481 · cited 1×
“All the recent international workshop-conferences on GDM[7,10,23-25] have recognized MNT as the cornerstone of therapy for women with GDM.”
BackgroundMaternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study
Jovanovic-Peterson, L., Peterson, C. M., Reed, G. F., Metzger, B. E., Mills, J. L., Knopp, R. H., & Aarons, J. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90637-7 · Cited by 411
Jovanovic, L. (2001) · JAMA · doi:10.1001/jama.286.20.2516 · Cited by 399
Gunderson, E. P., Murtaugh, M. A., Lewis, C. E., Quesenberry, C. P., West, D. S., & Sidney, S. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802551 · Cited by 252 · cited 1×
“Moreover, women who are overweight or obese before pregnancy are more likely to gain more weight related to childbearing.[34] Retention of gestational weight gain may contribute to obesity and increase the future risk for chronic diseases, including but not limited to type 2 diabetes.”
BackgroundDiurnal glycemic profile in obese and normal weight nondiabetic pregnant women
Yogev, Y., Ben-Haroush, A., Chen, R., Rosenn, B., Hod, M., & Langer, O. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.06.059 · Cited by 168 · cited 1×
“There is already an ongoing debate in the light of recent findings in normal pregnant women monitoring their own blood glucose levels[19] or using a CGMS[20,21] and because of the results of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study.”
ResultDhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145 · cited 1×
“also did a systematic review and meta-analysis to compare OHAs versus insulin in the management of gestational diabetes and concluded that there are no differences in glycemic control or pregnancy outcomes when OHAs were compared with insulin.[59] They recommended that metformin and glyburide should be considered as s…”
ResultMetformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.1.s60 · Cited by 114
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Transfer of metformin across the dually perfused human placental lobule
Nanovskaya, T. N., Nekhayeva, I. A., Patrikeeva, S. L., Hankins, G. D. V., & Ahmed, M. S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.047 · Cited by 98 · cited 1×
“Metformin has been found to have a maternal-to-fetal transfer rate of 10–16%.[74,75] Neonatal hypoglycemia is always a concern postnatally.”
BackgroundTransfer of glyburide and glipizide into breast milk
Feig, D. S., Briggs, G. G., Kraemer, J. M., Ambrose, P. J., Moskovitz, D. N., Nageotte, M., Donat, D. J., Padilla, G., Wan, S., Klein, J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1851 · Cited by 81
Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis
Goetzl, L., & Wilkins, I. (2002) · Journal of Perinatology · doi:10.1038/sj.jp.7210759 · Cited by 54 · cited 1×
“A cost analysis was then performed by Goetzl to compare the costs associated with glyburide versus insulin therapy.[55] Glyburide was found to be significantly less costly than insulin, with an average cost savings per patient of $165.”
MethodGlyburide crosses the placenta in vivo in pregnant rats
Sivan, E., Feldman, B., Dolitzki, M., Nevo, N., Dekel, N., & Karasik, A. (1995) · Diabetologia · doi:10.1007/s001250050348 · Cited by 44 · cited 1×
“Unlike other sulfonylureas, there is substantial evidence demonstrating the lack of transplacental passage of glyburide to the fetus,[48,49] suggesting insignificant fetal exposure with this drug and its safety in pregnancy.”
Background
Cited by
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Wei, J., Heng, W., & Gao, J. (2016) · Medicine · doi:10.1097/md.0000000000003792 · Cited by 62
Chaves, C., Cunha, F., Martinho, M., Garrido, S., Silva-Vieira, M., Estevinho, C., Melo, A., Figueiredo, O., Morgado, A., Almeida, M. C., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01665-8 · Cited by 12
Metadata
- Authors
- Magon, N., & Seshiah, V
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2011
- Volume
- 15
- Issue
- 4
- Pages
- 284
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W2161503473
- Cited by
- 58
- References
- 23
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.